Absci Corp (ABSI)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Absci Corp.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 1 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 7.80 $ — 59% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
Sells AIAbsci ist ein KI-natives Biotech, dessen gesamter Umsatz 2025 aus KI-gestützter Wirkstoff-Erzeugung (generative Plattform Origin-1) für Partner stammte — die KI ist nachweislich die alleinige Umsatzquelle, nicht nur ein Etikett.
View the full file — quotes, sources, reviewed filings
„We are a clinical-stage biopharmaceutical company using an AI-native approach to develop differentiated antibody therapeutics. Our integrated drug creation platform combines Origin-1, our generative design model, with rapid validation using our lab-in-the-loop."
Wir sind ein biopharmazeutisches Unternehmen im klinischen Stadium, das mit einem KI-nativen Ansatz differenzierte Antikörper-Therapeutika entwickelt. Unsere integrierte Wirkstoff-Erzeugungsplattform verbindet Origin-1, unser generatives Designmodell, mit einer schnellen Validierung durch unser lab-in-the-loop.
„For the year ended December 31, 2025, all of our revenue was generated by performing drug creation activities for our partnered programs."
Im Geschäftsjahr zum 31. Dezember 2025 wurde unser gesamter Umsatz durch die Durchführung von Wirkstoff-Erzeugungs-Tätigkeiten für unsere Partnerprogramme erwirtschaftet.
„The Company intends to use the net proceeds from this offering to fund the advancement of ABS-201, the Company's AI-designed anti-PRLR antibody product candidate, across androgenetic alopecia (pattern hair loss) and endometriosis."
Die Gesellschaft beabsichtigt, den Nettoerlös dieser Platzierung zur Weiterentwicklung von ABS-201 zu verwenden, dem KI-designten anti-PRLR-Antikörper-Kandidaten der Gesellschaft, in den Indikationen androgenetische Alopezie (erblich bedingter Haarausfall) und Endometriose.
Filings Reviewed: 10-K 2026-03-24 · 10-Q 2026-05-07 · 10-Q 2025-11-12 · 8-K 2026-06-24 · 10-K 2025-03-18
Rated on July 10, 2026 · How the Rating Is Built
Growth Score
4 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -21.3% failed
- More than 10% revenue growth is expected for the coming year 196.5% passed
- Share count grows by less than 3% a year 14.6% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -3,396.5% failed
- Gross margin at 40% or higher and without meaningful erosion -319.4% failed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 139 m net cash passed
- Operating cash flow covers the profits of the last three years 99 m failed
- Return on capital at 15% or higher, or up versus two years ago -64.4% failed
- Insiders hold at least 10% or are net buyers 12.1% passed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 76.7% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 9
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.78 | -0.96 – -0.59 | 6 | 11.5% | 9 |
| 12/31/2027 | -0.62 | -1.03 – -0.12 | 18 | 20.0% | 9 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.17 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.25 | – | 1 | 96.70 | -4,358.30 | -17 | -17 |
| 2025: Q1 | -0.21 | – | 1 | 31.30 | -2,234.60 | -22 | -22 |
| 2025: Q2 | -0.24 | – | 1 | -53.30 | -5,155.00 | -17 | -17 |
| 2025: Q3 | -0.20 | – | 0 | -77.80 | -7,594.20 | -25 | -26 |
| 2025: Q4 | -0.20 | – | 1 | -2.30 | -4,548.00 | -29 | -29 |
| 2026: Q1 | -0.19 | – | 0 | -81.80 | -13,767.00 | -26 | -26 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2019 | 2 | -6 | -7 | -0.07 | -6 | -41 | 19 |
| 2020 | 5 | -13 | -14 | -0.16 | -11 | 67 | 89 |
| 2021 | 5 | -75 | -101 | -1.09 | -61 | 366 | 426 |
| 2022 | 6 | -107 | -105 | -1.15 | -81 | 274 | 321 |
| 2023 | 6 | -116 | -111 | -1.20 | -65 | 176 | 217 |
| 2024 | 5 | -109 | -103 | -0.94 | -72 | 179 | 214 |
| 2025 | 3 | -125 | -115 | -0.84 | -93 | 189 | 216 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Absci Corporation, ein biopharmazeutisches Unternehmen in der klinischen Phase, entwickelt verschiedene Antikörpertherapeutika in den USA. Zu den präklinischen Entwicklungsprogrammen gehören ABS-101, das sich in einer klinischen Phase-1-Studie zur Behandlung chronisch-entzündlicher Darmerkrankungen befindet; ABS-201, ein Anti-Prolaktin-Rezeptor…
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 140 |
| Headquarters | Vancouver, WA |
| Address | 18105 SE Mill Plain Boulevard, 98683 Vancouver, United States |
| Phone | 360 949 1041 |
| Website | absci.com |
| IPO Date | 22. Jul 2021 |
| ISIN | US00091E1091 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Sean McClain | Founder, CEO, President & Director | 1990 |
| Zachariah Jonasson Ph.D. | Chief Business Officer & CFO | 1973 |
| Todd Bedrick CPA | Senior VP & Chief Accounting Officer | – |
| Alexander Khan CPA | CVP of Finance & Head of Investor Relations | – |
| Shelby Walker J.D. | Chief Legal Officer | 1975 |
| Jeanne Schreuder M.B.A., SPHR | Senior Vice President of People & Experience | – |
| Wen Sha | Chief of Staff | – |
| Christine Lemke D.V.M., M.B.A., Ph.D. | Senior Vice President of Portfolio & Growth Strategy | – |
| Ransi Somaratne FACC, M.B.A., M.D. | Chief Medical Officer | 1966 |
| Amer-Denis Akkad Ph.D. | Vice President of Research | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.